Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Pretransplant Plasma Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Are More Useful Prognostic Markers of Overall Survival after Allogeneic Hematopoietic Cell Transplantation Than Echocardiography

Naonori Harada, Hiroshi Okamura, MD PhD, Takahiko Nakane, MD PhD, Shiro Koh, MDPhD, Satoru Nanno, MD PhD, Mitsutaka Nishimoto, MD PhD, Asao Hirose, MD PhD, Mika Nakamae, MD PhD, Yasuhiro Nakashima, MD PhD, Hideo Koh, MD PhD, Masayuki Hino, MD PhD, Hirohisa Nakamae, MD PhD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134223

Published: 2020

Journal Articles

Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation

Nao Tanizawa, MD, Hideo Koh, MD PhD, Hiroshi Okamura, MD PhD, Koh Shiro, MD PhD, Satoru Nanno, MD PhD, Mitsutaka Nishimoto, MD PhD, Asao Hirose, MD PhD, Mika Nakamae, MD PhD, Yasuhiro Nakashima, MD PhD, Takahiko Nakane, MD PhD, Masayuki Hino, MD PhD, Hirohisa Nakamae, MD PhD

Blood (2019) 134 (Supplement_1): 4492.

https://doi.org/10.1182/blood-2019-124264

Published: 2019

Journal Articles

Impact of Donor KIR and HLA Genotypes on Clinical Outcomes According to Pre-Transplant Remission Status after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide

Kentaro Ido, MD, Hideo Koh, MD PhD, Hiroshi Okamura, MD PhD, Shiro Koh, MD PhD, Satoru Nanno, MD PhD, Mitsutaka Nishimoto, MD PhD, Asao Hirose, MD PhD, Mika Nakamae, MD PhD, Yasuhiro Nakashima, MD PhD, Takahiko Nakane, MD PhD, Masayuki Hino, MD PhD, Hirohisa Nakamae, MD PhD

Blood (2019) 134 (Supplement_1): 2030.

https://doi.org/10.1182/blood-2019-125173

Published: 2019

Journal Articles

Who Is the Best Donor for the Second Transplant?: HLA Discrepancy between Graft and Host Rather Than That Graft and First Donor May Impact the Second Transplant Outcome from the JSHCT

Yoshinobu Maeda, MD PhD, Tomotaka Ugai, MD, Eisei Kondo, Kazuhiro Ikegame, MD PhD, Makoto Murata, MD PhD, Naoyuki Uchida, MD PhD, Toshihiro Miyamoto, MD PhD, Satoshi Takahashi, MD PhD, Kazuteru Ohashi, MD PhD, Hirohisa Nakamae, MD PhD, Makoto Hirokawa, MD PhD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Yoshinobu Kanda, MD PhD, Junya Kanda, MD

Blood (2018) 132 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2018-99-112796

Published: 2018

Journal Articles

Pre-Transplant Serum Beta-2 Microglobulin Level Is a Potential Novel Prognostic Marker for Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Naonori Harada, Takahiko Nakane, MD PhD, Mika Nakamae, MD PhD, Hiroshi Okamura, Satoru Nanno, MD PhD, Mitsutaka Nishimoto, MD PhD, Yasunobu Takeoka, MD PhD, Asao Hirose, MD PhD, Yasuhiro Nakashima, MD PhD, Hideo Koh, MD PhD, Masayuki Hino, MD PhD, Hirohisa Nakamae, MD PhD

Blood (2018) 132 (Supplement 1): 4664.

https://doi.org/10.1182/blood-2018-99-111679

Published: 2018

Journal Articles

Noninvasive Diagnostic Approach By per Rectal Portal Scintigraphy for Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Cell Transplantation

Blood (2018) 132 (Supplement 1): 2087.

https://doi.org/10.1182/blood-2018-99-110517

Published: 2018

Journal Articles

Prophylactic Use of a Combination of an Anticoagulant and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation

Hiroshi Okamura, MD, Mitsutaka Nishimoto, MD,PhD, Takahiko Nakane, MD, PhD, Hideo Koh, MD,PhD, Yasuhiro Nakashima, MD, PhD, Yasunobu Takeoka, MD, PhD, Mika Nakamae, MD,PhD, Asao Hirose, MD, PhD, Masayuki Hino, MD, PhD, Hirohisa Nakamae, MD PhD

Blood (2016) 128 (22): 5755.

https://doi.org/10.1182/blood.V128.22.5755.5755

Published: 2016

Journal Articles

Combination of Frailty Status and Comorbidity Score Improves the Prediction of Survival in Patients with Myelodysplastic Syndrome Due to Good Predictive Capability for Infection-Related Mortality

Kazuki Sakatoku, MD, Yasunobu Takeoka, MD, PhD, Taku Araki, MD, Ryosuke Yamamura, MD, PhD, Takahiko Nakane, MD, PhD, Hirohisa Nakamae, MD PhD, Masayuki Hino, MD, PhD, Kensuke Ohta, MD, PhD

Blood (2016) 128 (22): 1995.

https://doi.org/10.1182/blood.V128.22.1995.1995

Published: 2016

Journal Articles

Safety and Efficacy of a Switch to Nilotinib in Patients with CML-CP Showing MMR to Imatinib: Results of a Multicenter Phase II Trial (NILSw Trial)

Hirohiko Shibayama, MD PhD, Tatsuya Kawaguchi, MD PhD, Junya Kuroda, MD PhD, Hirohisa Nakamae, MD PhD, Itaru Matsumura, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tomohiko Kamimura, MD PhD, Kentaro Fukushima, MD PhD, Yutaka Imamura, MD PhD, Tetsuya Eto, MD PhD, Kazutaka Sunami, MD PhD, Mototsugu Shimokawa, PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2016) 128 (22): 1914.

https://doi.org/10.1182/blood.V128.22.1914.1914

Published: 2016

Journal Articles

Short-Term Fasting Induces Cell Cycle Arrest of Immature Hematopoietic Cells and Increases the Number of Naive T Cells in the Bone Marrow of Mice

Teruhito Takakuwa, MD, Yasuhiro Nakashima, MD, PhD, Hideo Koh, MD,PhD, Takahiko Nakane, MD, PhD, Hirohisa Nakamae, MD PhD, Masayuki Hino, MD, PhD

Blood (2016) 128 (22): 5047.

https://doi.org/10.1182/blood.V128.22.5047.5047

Published: 2016

Journal Articles

Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial

Norimitsu Kadowaki, MD PhD, Tatsuya Kawaguchi, MD PhD, Junya Kuroda, MD PhD, Hirohisa Nakamae, MD PhD, Itaru Matsumura, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Koji Nagafuji, MD PhD, Yutaka Imamura, MD PhD, Hirohito Yamazaki, Mototsugu Shimokawa, PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2016) 128 (22): 790.

https://doi.org/10.1182/blood.V128.22.790.790

Published: 2016

Journal Articles

Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation

Takahiko Nakane, MD, PhD, Mika Nakamae, MD,PhD, Hideo Koh, MD,PhD, Mitsutaka Nishimoto, MD,PhD, Yoshiki Hayashi, MD,PhD, Asao Hirose, MD,PhD, Yasuhiro Nakashima, MD,PhD, Masayuki Hino, Hirohisa Nakamae, MD,PhD

Blood (2015) 126 (23): 3205.

https://doi.org/10.1182/blood.V126.23.3205.3205

Published: 2015

Journal Articles

Gvhd Prophylaxis With Mycophenolate Mofetil and Calcineurin Inhibitor In Allogeneic Hematopoietic Cell Transplantation From HLA-Matched Siblings Or 7–8/8 HLA-Matched Unrelated Volunteer Donors: A Japanese, Multicenter, Phase II Trial

Takahiko Nakane, M.D., Ph.D., Hirohisa Nakamae, MD, PhD, Saiko Kurosawa, MD, Atsuo Okamura, MD, PhD, Michihiro Hidaka, MD, PhD, Takuya Yamashita, MD, PhD, Akio Kohno, MD, PhD, Takeshi Saito, MD, Yasutaka Aoyama, MD, PhD, Kazuo Hatanaka, MD, Yoshio Katayama, MD, PhD, Kimikazu Yakushijin, MD, PhD, Toshimitsu Matsui, MD, PhD, Akiyoshi Takami, MD, PhD, Takuhiro Yamaguchi, PhD, Masayuki Hino, MD, PhD, Takahiro Fukuda, MD

Blood (2013) 122 (21): 4586.

https://doi.org/10.1182/blood.V122.21.4586.4586

Published: 2013

Journal Articles

A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

Manabu Hirai, MD, PHD, Takahiko Nakane, M.D., Ph.D., Atsushi Inoue, MD, Mitsuharu Hashimura, MD, Mizuki Aimoto, M.D., Erina Sakamoto, MD, PHD, Hirohisa Nakamae, MD, PhD, Masayuki Hino, MD, PhD

Blood (2013) 122 (21): 1536.

https://doi.org/10.1182/blood.V122.21.1536.1536

Published: 2013

Journal Articles

HLA Haplo-Identical Peripheral Blood Stem Cell Transplantation Using High-Dose Cyclophosphamide Post-Transplantation For Poor Prognosis Or Refractory Acute Leukemia and Myelodysplastic Syndrome: A Prospective Pilot Study At a Single Center

Hirohisa Nakamae, MD, PhD, Hideo Koh, M.D., Ph.D., Mitsutaka Nishimoto, M.D., Ph.D., Yasuhiro Nakashima, M.D., Ph.D., Satoru Nanno, M.D., Takuro Yoshimura, M.D., Ph.D., Shiro Koh, M.D., Hiroshi Okamura, M.D., Jyoji Nagasaki, M.D., Takahiko Nakane, M.D., Ph.D., Mika Nakamae, M.D., Ph.D., Asao Hirose, M.D., Ph.D., Masayuki Hino, MD, PhD

Blood (2013) 122 (21): 3404.

https://doi.org/10.1182/blood.V122.21.3404.3404

Published: 2013

Journal Articles

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Blood (2013) 122 (21): 3998.

https://doi.org/10.1182/blood.V122.21.3998.3998

Published: 2013

Journal Articles

Diagnostic Value Of Serum Level Of Soluble CD14-Subtype In Febrile Neutropenia In Patients With Hematologic Disorders

Hideo Koh, M.D., Ph.D., Hirohisa Nakamae, MD, PhD, Mizuki Aimoto, M.D., Takako Katayama, Asao Hirose, M.D., Ph.D., Mika Nakamae, M.D., Ph.D., Masayuki Hino, MD, PhD

Blood (2013) 122 (21): 4718.

https://doi.org/10.1182/blood.V122.21.4718.4718

Published: 2013

Journal Articles

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

Jorge E. Cortes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD, Neil P. Shah, MD, PhD, Jiri Mayer, MD, PhD, Philip Rowlings, MD, Hirohisa Nakamae, MD, PhD, M. Brigid Bradley-Garelik, MD, Hesham Mohamed, MD, Hagop M. Kantarjian, MD, Giuseppe Saglio, MD

Blood (2013) 122 (21): 653.

https://doi.org/10.1182/blood.V122.21.653.653

Published: 2013

Journal Articles

Cytomegalovirus Reactivation After Allogeneic Stem Cell Transplantation Is Associated With a Reduced Risk Of Relapse In Patients With Acute Myeloid Leukemia: The Japan Society For Hematopoietic Cell Transplantation (JSHCT) Transplantation-Related Complication Working Group

Katsuto Takenaka, M.D., PhD, Tetsuya Nishida, MD, PhD, Yuki Asano-Mori, MD, PhD, Kumi Oshima, MD, Gaku Oshikawa, MD, Koichi Miyamura, MD, PhD, Tetsuya Eto, MD, PhD, Hirohisa Nakamae, MD, PhD, Hisashi Sakamaki, MD, PhD, Yasuo Morishima, MD, Ritsuro Suzuki, MD, Takuhiro Yamaguchi, Ph.D., Takahiro Fukuda, MD

Blood (2013) 122 (21): 915.

https://doi.org/10.1182/blood.V122.21.915.915

Published: 2013

Journal Articles

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Giuseppe Saglio, Andreas Hochhaus, MD, Timothy P. Hughes, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Hirohisa Nakamae, MD, PhD, Dong-Wook Kim, MD, PhD, Saengsuree Jootar, Gabriel Etienne, MD, PHD, Ian Flinn, MD, PhD, Jeffrey H. Lipton, MD, PhD, Ricardo Pasquini, MD, PhD, Beatriz Moiraghi, MD, Charisse Kemp, Xiaolin Fan, PhD, Hans D. Menssen, MD, PhD, Hagop M. Kantarjian, MD, Richard A. Larson, MD

Blood (2013) 122 (21): 92.

https://doi.org/10.1182/blood.V122.21.92.92

Published: 2013

NARROW

Pretransplant Plasma Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide Are More Useful Prognostic Markers of Overall Survival after Allogeneic Hematopoietic Cell Transplantation Than Echocardiography

Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation

Impact of Donor KIR and HLA Genotypes on Clinical Outcomes According to Pre-Transplant Remission Status after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide

Who Is the Best Donor for the Second Transplant?: HLA Discrepancy between Graft and Host Rather Than That Graft and First Donor May Impact the Second Transplant Outcome from the JSHCT

Pre-Transplant Serum Beta-2 Microglobulin Level Is a Potential Novel Prognostic Marker for Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Noninvasive Diagnostic Approach By per Rectal Portal Scintigraphy for Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Cell Transplantation

Prophylactic Use of a Combination of an Anticoagulant and Ursodeoxycholic Acid for Sinusoidal Obstruction Syndrome after Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation

Combination of Frailty Status and Comorbidity Score Improves the Prediction of Survival in Patients with Myelodysplastic Syndrome Due to Good Predictive Capability for Infection-Related Mortality

Safety and Efficacy of a Switch to Nilotinib in Patients with CML-CP Showing MMR to Imatinib: Results of a Multicenter Phase II Trial (NILSw Trial)

Short-Term Fasting Induces Cell Cycle Arrest of Immature Hematopoietic Cells and Increases the Number of Naive T Cells in the Bone Marrow of Mice

Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial

Pre-Transplant Autonomic Nervous System Malfunction Is a Powerful Predictor for Survival after Allogeneic Hematopoietic Cell Transplantation

Gvhd Prophylaxis With Mycophenolate Mofetil and Calcineurin Inhibitor In Allogeneic Hematopoietic Cell Transplantation From HLA-Matched Siblings Or 7–8/8 HLA-Matched Unrelated Volunteer Donors: A Japanese, Multicenter, Phase II Trial

A New Strategy Of MDS Treatment With Azacitidine (AZA): Induction With AZA Combined With Low Dose AraC Followed By Maintenance Therapy With AZA

HLA Haplo-Identical Peripheral Blood Stem Cell Transplantation Using High-Dose Cyclophosphamide Post-Transplantation For Poor Prognosis Or Refractory Acute Leukemia and Myelodysplastic Syndrome: A Prospective Pilot Study At a Single Center

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Diagnostic Value Of Serum Level Of Soluble CD14-Subtype In Febrile Neutropenia In Patients With Hematologic Disorders

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

Cytomegalovirus Reactivation After Allogeneic Stem Cell Transplantation Is Associated With a Reduced Risk Of Relapse In Patients With Acute Myeloid Leukemia: The Japan Society For Hematopoietic Cell Transplantation (JSHCT) Transplantation-Related Complication Working Group

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only